Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357303 | 0.89 | KMT2A (0.43) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL1564210 | 0.78 | KMT2A (0.47) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL2332165 | 0.78 | ALDH1A1 (0.56) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL604671 | 0.78 | ALDH1A1 (0.56) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL3487387 | 0.78 | KMT2A (0.44) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL9607 | 0.77 | KMT2A (0.43) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL9254263 | 0.75 | KMT2A (0.42) | KMT2AATMALDH1A1PKMSLC1A2 | |
| Ethylene SCHEMBL29141463 | 0.75 | ALDH1A1 (0.53) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL30302184 | 0.75 | ALDH1A1 (0.53) | KMT2AATMALDH1A1PKMSLC1A2 | |
| Ethylene SCHEMBL8387032 | 0.75 | ALDH1A1 (0.53) | KMT2AATMALDH1A1PKMSLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4894229-A | ANTIGENS, LIPIDS, HAPTENS, CROSSLINKING AGENTS | SOUTH AFRICAN INVENTIONS DEVELOPMENT CORPORATION (ZA) | 1990-01-16 | — | — | US | claimed |
| US-7807133-B2 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-10-05 | — | — | US | disclosed |
| US-20090010839-A1 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy | SIGMA-TAU INDUSTRIE FARMACEUTICHE (IT) | 2009-01-08 | — | — | US | disclosed |
| US-7425317-B2 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy | SIGMA-TAU INDUSTRIE FARMACEUTICHE (IT) | 2008-09-16 | — | — | US | disclosed |
| EP-1482981-B1 | AVIDIN DIMERS EFFECTIVE IN INCREASING THE CONCENTRATION OF RADIOACTIVE BIOTIN IN PRETARGETED RADIOIMMUNOTHERAPY | SIGMA TAU IND FARMACEUTI (IT) | 2008-05-21 | — | — | EP | disclosed |
| US-20050106102-A1 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-05-19 | — | — | US | disclosed |
| EP-1482981-A1 | AVIDIN DIMERS EFFECTIVE IN INCREASING THE CONCENTRATION OF RADIOACTIVE BIOTIN IN PRETARGETED RADIOIMMUNOTHERAPY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003075960-A1 | AVIDIN DIMERS EFFECTIVE IN INCREASING THE CONCENTRATION OF RADIOACTIVE BIOTIN IN PRETARGETED RADIOIMMUNOTHERAPY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010839-A1 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy | NUCB2, BTD, BSG | KMT2A 4400/4885ATM 3044/4885ALDH1A1 2588/4885 |
| US-20050106102-A1 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy | BTD, NUCB2, BSG | KMT2A 4510/4885ATM 3242/4885ALDH1A1 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.